Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH18 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer

Nuclear Medicine and Biology

Volumn 38, Issue 4, 2011, Pages 509-515

  Denholt, Charlotte Lund ^a   Binderup, Tina ^a,b   Stockhausen, Marie Thérése ^a   Poulsen, Hans Skovgaard ^a   Spang Thomsen, Mogens ^c   Hansen, Paul Robert ^c   Gillings, Nic ^a   Kjær, Andreas ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; EGFRvIII; Fluorine 18 labelling; Molecular imaging; PET; Targeting peptides; Tumours

Indexed keywords

4 FLUOROBENZOIC ACID F 18; 4 FLUOROBENZOYL PHENYLALANYLLEUCYLGLYCYLGLUTAMYLALANYLAMIDE F 18; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ETHYL 4 (TRIMETHYLAMMONIUMTRIFLATE)BENZOATE; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; 4 FLUOROBENZOIC ACID; 4 FLUOROBENZOYL PHENYLALANYL ALANYL LEUCYL GLYCYL GLUTAMYL ALANINAMIDE; 4-FLUOROBENZOIC ACID; 4-FLUOROBENZOYL-PHENYLALANYL-ALANYL-LEUCYL-GLYCYL-GLUTAMYL-ALANINAMIDE; BENZOIC ACID DERIVATIVE; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACCUMULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOACTIVITY; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; TISSUE LEVEL; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DRUG STABILITY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; PATHOLOGY; SCINTISCANNING; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BENZOIC ACIDS; BIOLOGICAL TRANSPORT; CELL TRANSFORMATION, NEOPLASTIC; DRUG STABILITY; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MUTATION; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955467043     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.11.003     Document Type: Article

References (19)

1. Li G., Wong A.J. EGF receptor variant III as a target antigen for tumor immunotherapy. Exp Rev 2008, 7:977-985.
2. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19:2013-2023.
3. Yu H., Gong X., Lou X., Han W., Hong G., Singh B., et al. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 2008, 7:1818-1828.
4. Steffensen K.D., Waldstrøm M., Olsen D.A., Corydon T., Lorentzen K.A., Knudsen H.J., et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res 2008, 14:3278-3282.
5. Gan H.K., Kaye A.H., Luwor R.B. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009, 16:748-754.
6. Kamat V., Donaldson J.M., Kari C., Quadros M.R., Lelkes P.I., Chaiken I., et al. Inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 2008, 7:726-733.
7. Modjtahedi H., Moscatello D.K., Box G., Green M., Shotton C., Lamb D.J., et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 2003, 105:273-280.
8. McGregor D.P. Discovering and improving novel peptide therapeutics. Curr Opin Pharmacol 2008, 8:616-619.
9. Pal A., Glekas A., Doubrovin M., Balatoni J., Beresten T., Maxwell D., et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006, 8:262-277.
10. Denholt C.L., Hansen P.R., Pedersen N., Poulsen H.S., Gillings N., Kjær A. Identification of novel peptide ligands for EFGRvIII using a mixture-based synthetic combinatorial library. Biopolymers 2009, 91:201-206.
11. Sutcliffe-Goulden J.L., O'Doherty M.J., Marsden P.K., Hart I.R., Marshall J.F., Bansal S.S. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002, 29:754-759.
12. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995, 6:1251-1259.
13. Davenport A.P., Russell F.D. Radioligand binding assays: theory and practice. Current directions in radiopharmaceutical research and development 1996, 169-179. Kluwer Academic Publisher, Netherlands. S.J. Mather (Ed.).
14. Stockhausen M.T., Broholm H., Villingshøj M., Kirchhoff M., Gerdes T., Kristoffersen K., et al. Maintenance of EGFR and EGFRvIII expression in an in vivo and in vitro model of human glioblastoma multiforme 2010, Submitted to Neuro-Oncol.
15. Jensen M.M., Jorgensen J.T., Binderup T., Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008, 8:16.
16. Behr T.M., Goldenberg D.M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998, 25:201-212.
17. Decristoforo C., Knopp R., von Guggenberg E., Rupprich M., Dreger T., Hess A., et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007, 28:870-875.
18. νβ6 specific peptide radiolabeled using 18F-"click" chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl-and 2-[18F]fluoropropionyl-peptides. J Med Chem 2008, 51:5901-5904.
19. Tolmachev V., Carlsson J., Lundqvist H. A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy-availability of suitable radionuclides. Acta Oncol 2004, 43:264-275.